Pfizer (PFE) Tops Q1 EPS by 2c, Lowers FY Guidance Due to Exchange Rates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PFIZER REPORTS FIRST-QUARTER 2015 RESULTS
April 28, 2015 7:00 AM EDTFirst-Quarter 2015 Reported Revenues(1) of $10.9 Billion First-Quarter 2015 Adjusted Diluted EPS(2) of $0.51, Reported Diluted EPS(1) of $0.38; Both Adjusted Diluted EPS(2) and Reported Diluted EPS(1) Include a $0.03 Negative Impact Associated with an Upfront Payment to OPKO Health, Inc. (OPKO) Repurchased $6.0 Billion of Common Stock in First-Quarter 2015, Including a $5.0 Billion Accelerated Share Repurchase Agreement Executed in February Updated Certain Components of 2015 Financial Guidance Solely to Reflect the Negative Impact of Recent Changes in Foreign Exchange Rates
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:... More
